Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q3 EPS by 37c
Tweet
Share
E-mail
Get Alerts AMLX Hot Sheet
Join SI Premium – FREE
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q3 EPS of ($1.07), $0.37 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $416 thousand.
For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Diploma Plc. (DPLM:LN) to Overweight
- Hanmi Pharm licenses obesity drug to Genentech in $2.3B deal
- Morgan Stanley Starts Jersey Mike's Subs (JMKE) at Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
